Moderna, Inc.

We are mRNA. And mRNA is us.

Every day, we come together to create the blueprints needed to fight and eradicate diseases, and to help people live healthier lives. And the world has witnessed the powerful benefits of our platform technology.

With mRNA technology, we are completely reimagining how medicines are created and delivered. And in the process, we’re launching an entirely new industry, one fueled by deep care for our teams as well as for others.

Through the power of mRNA, we’re giving our people a platform to change medicine—and an opportunity to change the world.

Come with us as we pursue the uncharted reaches of possibility and make your mark on the future of medicine: modernatx.com/careers

200 Technology Square
Cambridge, MA

Tel: 617-714-6500

Visit website

Email Us

Stock Symbol: MRNA
Stock Exchange: USNASDAQ GS

Changing the future of medicine starts with our people. Across Moderna, our colleagues are working to make the impossible possible, and our goal is to support them every step of the way. With a global team and a unique culture, driven by the company’s values and mindsets, Moderna’s mission is to deliver the greatest possible impact to people through mRNA medicines.

Every Role Matters, Enabling Transformative Mission

At Moderna, our changemakers are actively building a better future, one innovation at a time. We recently asked Keke if she could create a six-word story about what being a changemaker meant to her.

Read Keke’s Story

Take your moment with benefits

We know that you will give us your all and we want to make sure that we’re doing the same for you and the people closest to you. We’re on this incredible journey of pushing past the possible together, which is why we provide paramount support for both you and your family.

Learn More

NEWS

Contemporary artwork. Businessman jumping over bear trap with briefcase and documents. Concept of business risk, hidden financial dangers, legal pitfalls, investment fraud and consumer protection.

Vaccines

Flu Vaccine Rejection Imperils Moderna’s Breakeven Plans

Moderna’s mRNA-1010 was expected to contribute $1 billion to the company’s coffers by 2028. That plan is now out the window after the FDA refused to even look at the application.

February 12, 2026

4 min read

Dan Samorodnitsky

Pictured: A syringe broken in half with long hallway in background/Nicole Bean for BioSpace

Regulatory

HHS Backs Prasad Amid Moderna Flu Shot Blowback

An unnamed FDA official also told reporters that it would be good for Moderna to “show some humility” and admit that it didn’t follow the regulator’s recommendations in testing its mRNA flu vaccine.

February 12, 2026

2 min read

Tristan Manalac

3d rendering, Business e-mail. Open envelope with cross mark on sheet of paper. Rejected contract, document cancelled, not verified.

Editorial

All the Ways Moderna’s Flu Vaccine Rejection Letter Shocked Us

The FDA issued a rare Refusal-to-File letter to Moderna over its mRNA-based influenza vaccine application, in an unusual move that sent the biotech’s shares tumbling.

February 11, 2026

4 min read

Dan Samorodnitsky

Hiring collage showing HR checking applicant information

Job Trends

Hiring Outlook: January Brings Year-Over-Year Layoff Decline

Last month, biopharmas let go or projected they would let go of less than 500 people combined, based on BioSpace estimates, down almost 1,000 from January 2025. Still, competition for open jobs remains strong, with employed and unemployed biotech and pharma professionals eyeing their next roles.

February 11, 2026

4 min read

Angela Gabriel

Syringe and a vial above the map of the USA. Illustration of the concept of the vaccination and immunization in the United States

Vaccines

FDA Refuses To Review Moderna’s mRNA Flu Vaccine, Claims Trial Inadequacies

After receiving a letter directly from CBER Director Vinay Prasad, Moderna said the FDA had previously signed off on the use of a licensed flu vaccine as a comparator for a Phase 3 study of mRNA-1010.

February 11, 2026

4 min read

Tristan Manalac

A teamwork with different purpose. Isolated Vector illustration

Drug Development

BioNTech’s Multi-Modality Play Outpaces Moderna’s mRNA-Focused Pipeline

After advancing in lockstep through the pandemic, the fortunes of the biotechs have diverged as their use of COVID-19 windfalls has taken shape.

February 3, 2026

5 min read

Nick Paul Taylor

Deals

Moderna Teams With Recordati on Rare Disease mRNA Therapy for up to $160M

Moderna will continue to lead clinical development and manufacturing of the asset, while Recordati will handle commercialization of mRNA-3927, which is under development for the rare metabolic disorder propionic acidemia.

January 30, 2026

1 min read

Annalee Armstrong

Podcast

Roche Makes Obesity Splash, Moderna Cans Vaccine Trials, Sarepta’s New Data, More

Roche’s obesity candidate achieves 22.5% weight loss in Phase II; Moderna pulls the plug on late-stage vaccine trials as Health Secretary Robert F. Kennedy’s anti-vaccine policies and rhetoric continues; and embattled gene therapy maker Sarepta announces new data in Duchenne muscular dystrophy.

January 28, 2026

1 min read

Heather McKenzie

Vaccines

Moderna Won’t Run Phase III Vaccine Trials as Skepticism Grows in US: Bloomberg

Growing opposition to vaccines in the U.S., driven by recent government policy changes, makes it difficult to see a return on investment in vaccine development, Moderna CEO Stéphane Bancel said this week.

January 23, 2026

2 min read

Tristan Manalac

JOBS